DeepMed Research

Nepafenac

Generic Name: Nepafenac

Brand Names: Ilevro, Nevanac

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₄N_₂O_₂

CAS Number: 78281-72-8

Unique Ingredient Identifier: 0J9L7J6V8C

Background: Nepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery.

Indication: For the treatment of pain and inflammation associated with cataract surgery.

Associated Conditions: Inflammation, Pain

Clinical Trials

Nepafenac Once Daily for Macular Edema - Study 1

Phase 3

Completed

Conditions: Non-Proliferative Diabetic Retinopathy
Cataract

Interventions: Other: Nepafenac vehicle
Drug: Nepafenac Ophthalmic Suspension, 0.3%
Drug: Prednisolone acetate

First Posted Date: 2013-05-14

Last Posted Date: 2016-08-03

Lead Sponsor: Alcon Research

Target Recruit Count: 881

Registration Number: NCT01853072

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery

Not Applicable

Completed

Conditions: Retinal Edema
Inflammation
Cataract

Interventions: Drug: Prolensa (bromfenac 0.07%)
Drug: Ilevro (nepafenac 0.3%)

First Posted Date: 2013-05-07

Last Posted Date: 2018-11-14

Lead Sponsor: Melissa Toyos

Target Recruit Count: 50

Registration Number: NCT01847638

Locations: 🇺🇸
Toyos Clinic, Nashville, Tennessee, United States

Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification

Phase 2

Completed

Conditions: Phacoemulsification Cataract Surgery
Cataract

Interventions: Drug: Nevanac
Drug: PRO-155

First Posted Date: 2012-08-06

Last Posted Date: 2018-10-30

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 160

Registration Number: NCT01657266

Locations: 🇲🇽
Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico

Nepafenac Compared to Placebo for Ocular Pain and Inflammation

Phase 3

Completed

Conditions: Cataract

Interventions: Drug: Nepafenac Ophthalmic Suspension, 0.1%
Other: Nepafenac Vehicle Ophthalmic Solution

First Posted Date: 2011-09-01

Last Posted Date: 2013-05-13

Lead Sponsor: Alcon Research

Target Recruit Count: 260

Registration Number: NCT01426854

Locations: 🇨🇳
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China

Prophylactic Nepafenac and Ketorolac Versus Placebo in Patients Undergoing Cataract Surgery

Phase 4

Completed

Conditions: Macular Edema

Interventions: Drug: Ketorolac 0.5%
Drug: Nepafenac 0.1%
Other: Placebo (sterile saline drops)

First Posted Date: 2011-07-15

Last Posted Date: 2016-01-13

Lead Sponsor: Queen's University

Target Recruit Count: 162

Registration Number: NCT01395069

Locations: 🇨🇦
Hotel Dieu Hospital, Kingston, Ontario, Canada

NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)

Phase 2

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: nepafenac 0.1% drops
Other: Nepafenac Vehicle

First Posted Date: 2011-04-07

Last Posted Date: 2025-03-10

Lead Sponsor: Jaeb Center for Health Research

Target Recruit Count: 125

Registration Number: NCT01331005

Locations: 🇺🇸
Joslin Diabetes Center, Boston, Massachusetts, United States
🇺🇸
Paducah Retinal Center, Paducah, Kentucky, United States
🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

and more 29 locations

Nepafenac 0.3% Two Study

Phase 2

Completed

Conditions: Cataract

Interventions: Drug: Nepafenac Ophthalmic Suspension, 0.3%
Drug: Nepafenac Ophthalmic Suspension, 0.1%
Other: Nepafenac Vehicle 0.3%

First Posted Date: 2011-03-18

Last Posted Date: 2012-12-17

Lead Sponsor: Alcon Research

Target Recruit Count: 1342

Registration Number: NCT01318499

Locations: 🇺🇸
Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Phase 4

Completed

Conditions: Inflammation
Pseudophakia

Interventions: Drug: Bromfenac
Drug: Nepafenac

First Posted Date: 2011-03-08

Last Posted Date: 2020-10-28

Lead Sponsor: Toyos Clinic

Target Recruit Count: 23

Registration Number: NCT01310127

Confirmatory Study Nepafenac 0.3%

Phase 3

Completed

Conditions: Cataract

Interventions: Drug: Nepafenac Ophthalmic Suspension, 0.3%
Drug: Nepafenac Ophthalmic Suspension, 0.1%
Other: Nepafenac Ophthalmic Suspension 0.3% Vehicle
Other: NEVANAC Vehicle

First Posted Date: 2010-04-23

Last Posted Date: 2012-11-30

Lead Sponsor: Alcon Research

Target Recruit Count: 2120

Registration Number: NCT01109173

Locations: 🇺🇸
Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States

A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification

Phase 4

Completed

Conditions: Cataracts

Interventions: Drug: Bromfenac
Drug: nepafenac
Drug: Ketorolac Tromethamine

First Posted Date: 2009-11-30

Last Posted Date: 2011-08-31

Lead Sponsor: Frank A. Bucci, Jr., M.D.

Target Recruit Count: 126

Registration Number: NCT01021761

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy